Shopping Cart 0
Cart Subtotal
AED 0

IBS Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) - Americas Forecast Till 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 16332

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22938

Details

IBS Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories)-Americas Forecast Till 2023

Market Analysis

Irritable bowel syndrome (IBS) is one of the major disorders affecting the digestive system of humans. Diarrhea, bloating, stomach cramps, and constipation, are some of the symptoms of the disorder. In spite of the fact that the reason for IBS is obscure, however, few factors that cause IBS are extreme disease, inflammation of the digestion tracts, contraction of muscles in the intestine, changes in gut bacteria, and nerve disorders. The rising pervasiveness of gastrointestinal infections and confusion, the geriatric populace, undesirable eating regimen, uneasiness, depression, and changing way of life in the Americas are the key drivers of the Americas IBS market. The Americas IBS treatment market is projected to grow at a CAGR of 9.3% during the forecast period 2017-2023.

Moreover, expanding consumer awareness about the IBS syndrome has increased the footfall of patient in the hospitals and other healthcare centers. Moreover, expanding expenditure in the medicinal services area is fueling the development of the IBS treatment market. However, strict FDA controls and inadmissible adequacy of the treatment may harm the development of the Americas IBS treatment market amid the forecast period (2017-2023).

Market Segmentation

The Americas IBS treatment market is segmented on the basis of its drugs type, types, end user and regional analysis. Based on its drugs type, the Americas IBS treatment market is sectioned into linaclotide, lubiprostone, eluxadoline, alosetron, rifaximin, and others. On the basis its types, the market is classified into IBS-C, IBS-D, IBS-M. Based on its end users, it is divided into clinics, research laboratories, and hospitals.

Regional Analysis

Geographically, the Americas IBS treatment market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major Players

The list of key players in Americas IBS treatment market include companies like Allergan Plc (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc. (Japan), Abbott Laboratories (U.S.), Valeant Pharmaceuticals (Canada), Synergy Pharmaceuticals, Inc. (U.S.), Nestle (Switzerland), Ardelyx, Inc. (U.S.), Sebela Pharmaceuticals (Ireland), Alfasigma USA, Inc. (Italy), Probi (Sweden), RedHill Biopharma Ltd. (Israel), Ipsen (France), AstraZeneca (U.K), Novartis AG (Switzerland), Synthetic Biologics, Inc. (U.S.), Takeda Pharmaceutical Company Ltd (Japan), Protagonist Therapeutics Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), 4D pharma plc (U.K), Innovate Biopharmaceuticals (U.S.), among others.

READ MORE

Table Of Content

Scope

Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Scope of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

2.4 Market Structure

3 Research Methodology

3.1.1 Primary Research Methodology

3.1.2 Data points received from the doctors/ gastrologist:

3.1.3 Data points received from the manufacturer/ pharmaceutical companies:

3.1.4 Data points received from Hospitals, Clinics:

3.1.5 Secondary Research Methodology

3.1.6 Market Share Analysis

3.1.7 Trade Analysis

3.1.8 Market Pricing Approach

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Increasing prevalence of anxiety (Impact Weightage: 37%)

4.2.2 Strong clinical pipeline (Impact Weightage: 35%)

4.2.3 Increasing prevalence of depression (Impact Weightage: 28%)

4.3 Restraints

4.3.1 Strict FDA regulations (Impact Weightage: 60%)

4.3.2 Unsatisfactory effectiveness of the treatment (Impact Weightage: 40%)

4.4 Opportunity

4.5 Mega Trends

4.6 Macroeconomic Indicators

5 Market Factor Analysis

5.1 Value Chain Analysis

5.1.1 Research and Development

5.1.2 Manufacturing

5.1.3 Distribution & Sales

5.1.4 Post-sales Monitoring

5.2 Porters Five Forces

5.2.1 Threat of New Entrants (Medium to High)

5.2.2 Bargaining power of suppliers (Medium)

5.2.3 Threat of Substitutes (Medium to High)

5.2.4 Bargaining Power of Buyers (Medium)

5.2.5 Intensity of Rivalry (Medium to High)

5.3 Demand & Supply: Gap Analysis

5.4 Pricing Analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

6 Americas IBS Treatment Market, By Type

6.1 Introduction

6.2 IBS-D

6.3 IBS-C

6.4 IBS-M

7 Americas IBS Treatment Market, By Drug Type

7.1 Introduction

7.2 Lubiprostone

7.3 Linaclotide

7.4 Eluxadoline

7.5 Rifaximin

7.6 Alosetron

8 Americas IBS Treatment Market, By End User

8.1 Introduction

8.2 Hospitals

8.3 Clinics

8.4 Research laboratories

9 Americas IBS treatment By Region

9.1 Introduction

9.1.1 North America

9.1.1.1 U.S.

9.1.1.2 Canada

9.1.2 South America

10 Company Landscape

11 Company Profiles

11.1 Allergan Plc

11.1.1 Company Overview

11.1.2 Financials

11.1.3 Products

11.1.4 Strategy

11.1.5 Key Developments

11.2 Sucampo Pharmaceuticals

11.2.1 Company Overview

11.2.2 Financials

11.2.3 Products

11.2.4 Strategy

11.2.5 Key Developments

11.3 Ironwood Pharmaceuticals, Inc.

11.3.1 Company Overview

11.3.2 Financials

11.3.3 Products

11.3.4 Strategy

11.3.5 Key Developments

11.4 Astellas Pharma Inc.

11.4.1 Company Overview

11.4.2 Financials

11.4.3 Products

11.4.4 Strategy

11.4.5 Key Developments

11.5 Valeant Pharmaceuticals

11.5.1 Company Overview

11.5.2 Financials

11.5.3 Products

11.5.4 Strategy

11.5.5 Key Developments

11.6 Abbott Laboratories

11.6.1 Company Overview

11.6.2 Financials

11.6.3 Products

11.6.4 Strategy

11.6.5 Key Developments

11.7 Synergy Pharmaceuticals, Inc.

11.7.1 Company Overview

11.7.2 Financials

11.7.3 Products

11.7.4 Strategy

11.7.5 Key Developments

11.8 Ardelyx, Inc.

11.8.1 Company Overview

11.8.2 Financials

11.8.3 Products

11.8.4 Strategy

11.8.5 Key Developments

11.9 Nestle

11.9.1 Company Overview

11.9.2 Financials

11.9.3 Products

11.9.4 Strategy

11.9.5 Key Developments

11.1 Sebela Pharmaceuticals

11.10.1 Company Overview

11.10.2 Financials

11.10.3 Products

11.10.4 Strategy

11.10.5 Key Developments

11.11 Probi

11.11.1 Company Overview

11.11.2 Financials

11.11.3 Products

11.11.4 Strategy

11.11.5 Key Developments

11.12 Alfasigma USA, Inc.

11.12.1 Company Overview

11.12.2 Financials

11.12.3 Products

11.12.4 Strategy

11.12.5 Key Developments

12 Conclusion

12.1 Key Findings

12.1.1 From CEO's View Point

12.1.2 Unmet Needs

12.2 Key Companies to Watch

13 Appendix

13.1 Discussion Blue Print


List Of Figure

List of Figures:

FIGURE 1 AMERICAS IBS TREATMENT MARKET SHARE, BY TYPE, 2016 (%)

FIGURE 2 AMERICAS IBS TREATMENT MARKET SHARE, BY DRUG TYPE, 2016 (%)

FIGURE 3 RESEARCH METHODOLOGY

FIGURE 4 DATA TRIANGULATION PRIMARY

FIGURE 5 DATA TRIANGULATION METHOD

FIGURE 6 VALUE CHAIN: IRRITABLE BOWEL SYNDROME

FIGURE 7 PORTERS FIVE FORCES MODEL

FIGURE 8 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2016 & 2023 (USD MILLION)

FIGURE 9 AMERICAS IBS TREATMENT MARKET, BY END USER, 2016 & 2023 (USD MILLION)

FIGURE 10 AMERICAS IBS TREATMENT MARKET, BY REGION MARKET SHARE, 2016 (%)

FIGURE 11 AMERICAS IBS TREATMENT COMPANY MARKET SHARE, 2016 (%)


List Of Table

List of Tables:

TABLE 1 PRIMARY INTERVIEWS

TABLE 2 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 3 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2016 & 2023 (USD MILLION)

TABLE 4 AMERICAS IBS TREATMENT MARKET FOR IBS-D SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 5 AMERICAS IBS TREATMENT MARKET FOR IBS-C SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 6 AMERICAS IBS TREATMENT MARKET FOR IBS-M SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 7 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 8 AMERICAS IBS TREATMENT MARKET FOR LUBIPROSTONE SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 9 AMERICAS IBS TREATMENT MARKET FOR LINACLOTIDE SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 10 AMERICAS IBS TREATMENT MARKET FOR ELUXADOLINE SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 11 AMERICAS IBS TREATMENT MARKET FOR RIFAXIMIN SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 12 AMERICAS IBS TREATMENT MARKET FOR ALOSETRON SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 13 AMERICAS IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 14 AMERICAS IBS TREATMENT MARKET FOR HOSPITALS SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 15 AMERICAS IBS TREATMENT MARKET FOR CLINICS SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 16 AMERICAS IBS TREATMENT MARKET FOR RESEARCH LABORATORIES SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 17 AMERICAS IBS TREATMENT MARKET, BY REGION 2014-2023 (USD MILLION)

TABLE 18 NORTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 19 NORTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 20 NORTH AMERICA IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 21 U.S. IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 22 U.S. IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 23 U.S. IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 24 CANADA IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 25 CANADA IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 26 CANADA IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 27 SOUTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 28 SOUTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 29 SOUTH AMERICA IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

Licence Rights

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Allergan Plc (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc. (Japan), Abbott Laboratories (U.S.), Valeant Pharmaceuticals (Canada), Synergy Pharmaceuticals, Inc. (U.S.), Nestle (Switzerland), Ardelyx, Inc. (U.S.), Sebela Pharmaceuticals (Ireland), Alfasigma USA, Inc. (Italy), Probi (Sweden), RedHill Biopharma Ltd. (Israel), Ipsen (France), AstraZeneca (U.K), Novartis AG (Switzerland), Synthetic Biologics, Inc. (U.S.), Takeda Pharmaceutical Company Ltd (Japan), Protagonist Therapeutics Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), 4D pharma plc (U.K), Innovate Biopharmaceuticals (U.S.), among others.

Company Profile

Company Profile Title

IBS Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories)-Americas Forecast Till 2023

Market Analysis

Irritable bowel syndrome (IBS) is one of the major disorders affecting the digestive system of humans. Diarrhea, bloating, stomach cramps, and constipation, are some of the symptoms of the disorder. In spite of the fact that the reason for IBS is obscure, however, few factors that cause IBS are extreme disease, inflammation of the digestion tracts, contraction of muscles in the intestine, changes in gut bacteria, and nerve disorders. The rising pervasiveness of gastrointestinal infections and confusion, the geriatric populace, undesirable eating regimen, uneasiness, depression, and changing way of life in the Americas are the key drivers of the Americas IBS market. The Americas IBS treatment market is projected to grow at a CAGR of 9.3% during the forecast period 2017-2023.

Moreover, expanding consumer awareness about the IBS syndrome has increased the footfall of patient in the hospitals and other healthcare centers. Moreover, expanding expenditure in the medicinal services area is fueling the development of the IBS treatment market. However, strict FDA controls and inadmissible adequacy of the treatment may harm the development of the Americas IBS treatment market amid the forecast period (2017-2023).

Market Segmentation

The Americas IBS treatment market is segmented on the basis of its drugs type, types, end user and regional analysis. Based on its drugs type, the Americas IBS treatment market is sectioned into linaclotide, lubiprostone, eluxadoline, alosetron, rifaximin, and others. On the basis its types, the market is classified into IBS-C, IBS-D, IBS-M. Based on its end users, it is divided into clinics, research laboratories, and hospitals.

Regional Analysis

Geographically, the Americas IBS treatment market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major Players

The list of key players in Americas IBS treatment market include companies like Allergan Plc (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc. (Japan), Abbott Laboratories (U.S.), Valeant Pharmaceuticals (Canada), Synergy Pharmaceuticals, Inc. (U.S.), Nestle (Switzerland), Ardelyx, Inc. (U.S.), Sebela Pharmaceuticals (Ireland), Alfasigma USA, Inc. (Italy), Probi (Sweden), RedHill Biopharma Ltd. (Israel), Ipsen (France), AstraZeneca (U.K), Novartis AG (Switzerland), Synthetic Biologics, Inc. (U.S.), Takeda Pharmaceutical Company Ltd (Japan), Protagonist Therapeutics Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), 4D pharma plc (U.K), Innovate Biopharmaceuticals (U.S.), among others.

READ MORE

Scope

Table of Contents:

1 Report Prologue

2 Market Introduction

2.1 Scope of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

2.4 Market Structure

3 Research Methodology

3.1.1 Primary Research Methodology

3.1.2 Data points received from the doctors/ gastrologist:

3.1.3 Data points received from the manufacturer/ pharmaceutical companies:

3.1.4 Data points received from Hospitals, Clinics:

3.1.5 Secondary Research Methodology

3.1.6 Market Share Analysis

3.1.7 Trade Analysis

3.1.8 Market Pricing Approach

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Increasing prevalence of anxiety (Impact Weightage: 37%)

4.2.2 Strong clinical pipeline (Impact Weightage: 35%)

4.2.3 Increasing prevalence of depression (Impact Weightage: 28%)

4.3 Restraints

4.3.1 Strict FDA regulations (Impact Weightage: 60%)

4.3.2 Unsatisfactory effectiveness of the treatment (Impact Weightage: 40%)

4.4 Opportunity

4.5 Mega Trends

4.6 Macroeconomic Indicators

5 Market Factor Analysis

5.1 Value Chain Analysis

5.1.1 Research and Development

5.1.2 Manufacturing

5.1.3 Distribution & Sales

5.1.4 Post-sales Monitoring

5.2 Porters Five Forces

5.2.1 Threat of New Entrants (Medium to High)

5.2.2 Bargaining power of suppliers (Medium)

5.2.3 Threat of Substitutes (Medium to High)

5.2.4 Bargaining Power of Buyers (Medium)

5.2.5 Intensity of Rivalry (Medium to High)

5.3 Demand & Supply: Gap Analysis

5.4 Pricing Analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

6 Americas IBS Treatment Market, By Type

6.1 Introduction

6.2 IBS-D

6.3 IBS-C

6.4 IBS-M

7 Americas IBS Treatment Market, By Drug Type

7.1 Introduction

7.2 Lubiprostone

7.3 Linaclotide

7.4 Eluxadoline

7.5 Rifaximin

7.6 Alosetron

8 Americas IBS Treatment Market, By End User

8.1 Introduction

8.2 Hospitals

8.3 Clinics

8.4 Research laboratories

9 Americas IBS treatment By Region

9.1 Introduction

9.1.1 North America

9.1.1.1 U.S.

9.1.1.2 Canada

9.1.2 South America

10 Company Landscape

11 Company Profiles

11.1 Allergan Plc

11.1.1 Company Overview

11.1.2 Financials

11.1.3 Products

11.1.4 Strategy

11.1.5 Key Developments

11.2 Sucampo Pharmaceuticals

11.2.1 Company Overview

11.2.2 Financials

11.2.3 Products

11.2.4 Strategy

11.2.5 Key Developments

11.3 Ironwood Pharmaceuticals, Inc.

11.3.1 Company Overview

11.3.2 Financials

11.3.3 Products

11.3.4 Strategy

11.3.5 Key Developments

11.4 Astellas Pharma Inc.

11.4.1 Company Overview

11.4.2 Financials

11.4.3 Products

11.4.4 Strategy

11.4.5 Key Developments

11.5 Valeant Pharmaceuticals

11.5.1 Company Overview

11.5.2 Financials

11.5.3 Products

11.5.4 Strategy

11.5.5 Key Developments

11.6 Abbott Laboratories

11.6.1 Company Overview

11.6.2 Financials

11.6.3 Products

11.6.4 Strategy

11.6.5 Key Developments

11.7 Synergy Pharmaceuticals, Inc.

11.7.1 Company Overview

11.7.2 Financials

11.7.3 Products

11.7.4 Strategy

11.7.5 Key Developments

11.8 Ardelyx, Inc.

11.8.1 Company Overview

11.8.2 Financials

11.8.3 Products

11.8.4 Strategy

11.8.5 Key Developments

11.9 Nestle

11.9.1 Company Overview

11.9.2 Financials

11.9.3 Products

11.9.4 Strategy

11.9.5 Key Developments

11.1 Sebela Pharmaceuticals

11.10.1 Company Overview

11.10.2 Financials

11.10.3 Products

11.10.4 Strategy

11.10.5 Key Developments

11.11 Probi

11.11.1 Company Overview

11.11.2 Financials

11.11.3 Products

11.11.4 Strategy

11.11.5 Key Developments

11.12 Alfasigma USA, Inc.

11.12.1 Company Overview

11.12.2 Financials

11.12.3 Products

11.12.4 Strategy

11.12.5 Key Developments

12 Conclusion

12.1 Key Findings

12.1.1 From CEO's View Point

12.1.2 Unmet Needs

12.2 Key Companies to Watch

13 Appendix

13.1 Discussion Blue Print


List Of Figure

List of Figures:

FIGURE 1 AMERICAS IBS TREATMENT MARKET SHARE, BY TYPE, 2016 (%)

FIGURE 2 AMERICAS IBS TREATMENT MARKET SHARE, BY DRUG TYPE, 2016 (%)

FIGURE 3 RESEARCH METHODOLOGY

FIGURE 4 DATA TRIANGULATION PRIMARY

FIGURE 5 DATA TRIANGULATION METHOD

FIGURE 6 VALUE CHAIN: IRRITABLE BOWEL SYNDROME

FIGURE 7 PORTERS FIVE FORCES MODEL

FIGURE 8 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2016 & 2023 (USD MILLION)

FIGURE 9 AMERICAS IBS TREATMENT MARKET, BY END USER, 2016 & 2023 (USD MILLION)

FIGURE 10 AMERICAS IBS TREATMENT MARKET, BY REGION MARKET SHARE, 2016 (%)

FIGURE 11 AMERICAS IBS TREATMENT COMPANY MARKET SHARE, 2016 (%)


List Of Table

List of Tables:

TABLE 1 PRIMARY INTERVIEWS

TABLE 2 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 3 AMERICAS IBS TREATMENT MARKET, BY TYPE, 2016 & 2023 (USD MILLION)

TABLE 4 AMERICAS IBS TREATMENT MARKET FOR IBS-D SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 5 AMERICAS IBS TREATMENT MARKET FOR IBS-C SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 6 AMERICAS IBS TREATMENT MARKET FOR IBS-M SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 7 AMERICAS IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 8 AMERICAS IBS TREATMENT MARKET FOR LUBIPROSTONE SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 9 AMERICAS IBS TREATMENT MARKET FOR LINACLOTIDE SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 10 AMERICAS IBS TREATMENT MARKET FOR ELUXADOLINE SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 11 AMERICAS IBS TREATMENT MARKET FOR RIFAXIMIN SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 12 AMERICAS IBS TREATMENT MARKET FOR ALOSETRON SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 13 AMERICAS IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 14 AMERICAS IBS TREATMENT MARKET FOR HOSPITALS SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 15 AMERICAS IBS TREATMENT MARKET FOR CLINICS SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 16 AMERICAS IBS TREATMENT MARKET FOR RESEARCH LABORATORIES SEGMENT, BY REGION, 2014-2023 (USD MILLION)

TABLE 17 AMERICAS IBS TREATMENT MARKET, BY REGION 2014-2023 (USD MILLION)

TABLE 18 NORTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 19 NORTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 20 NORTH AMERICA IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 21 U.S. IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 22 U.S. IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 23 U.S. IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 24 CANADA IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 25 CANADA IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 26 CANADA IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

TABLE 27 SOUTH AMERICA IBS TREATMENT MARKET, BY TYPE, 2014-2023 (USD MILLION)

TABLE 28 SOUTH AMERICA IBS TREATMENT MARKET, BY DRUG TYPE, 2014-2023 (USD MILLION)

TABLE 29 SOUTH AMERICA IBS TREATMENT MARKET, BY END USER, 2014-2023 (USD MILLION)

"Single User License: OnIine PDF View Only
Enterprise-user License : Print & download option is available."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Allergan Plc (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc. (Japan), Abbott Laboratories (U.S.), Valeant Pharmaceuticals (Canada), Synergy Pharmaceuticals, Inc. (U.S.), Nestle (Switzerland), Ardelyx, Inc. (U.S.), Sebela Pharmaceuticals (Ireland), Alfasigma USA, Inc. (Italy), Probi (Sweden), RedHill Biopharma Ltd. (Israel), Ipsen (France), AstraZeneca (U.K), Novartis AG (Switzerland), Synthetic Biologics, Inc. (U.S.), Takeda Pharmaceutical Company Ltd (Japan), Protagonist Therapeutics Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Pfizer Inc (U.S.), 4D pharma plc (U.K), Innovate Biopharmaceuticals (U.S.), among others.